Netupitant / Palonosetron Capsules Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 300 mg netupitant and 0.5 mg palonosetron
Reference Brands: Akynzeo(US & EU)
Category:
Antiemetic
Netupitant + Palonosetron capsules block neurokinin-1 and 5-HT3 receptors, respectively. This dual action prevents nausea and vomiting caused by chemotherapy. Benefits include long-lasting antiemetic control, improved patient comfort, fewer breakthrough symptoms, enhanced adherence to cancer treatments, and better quality of life during chemotherapy.
Netupitant / Palonosetron Capsules is available in Capsules
and strengths such as 300 mg netupitant and 0.5 mg palonosetron.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Netupitant / Palonosetron Capsules is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Netupitant / Palonosetron Capsules can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Netupitant + Palonosetron capsules, marketed as Akynzeo, are approved in the US by the FDA and in the EU via EMA for preventing chemotherapy-induced nausea and vomiting. Regulatory approval requires a detailed dossier including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. The FDA reviews comprehensive clinical trial and quality data for timely approval, while the EMA ensures compliance with regional safety and manufacturing regulations. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper adherence supports swift approval, safe use, and global availability, helping cancer patients better manage nausea and improve treatment adherence worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing